VIVUS is a commercial-stage biopharmaceutical company focused on leveraging it clinical development and commercialization expertise to address unmet need. The company has established the VIVUS Health Platform as an innovative health solution that integrates pharmaceuticals, technology, clinical stakeholders and market access programs into a true health solution that improves patient outcomes by making it easier for patients to access, adhere to and benefit from clinically proven therapies.
VIVUS’ commercial portfolio comprises three assets in large markets: QYSMIA for body mass index management; PANCREAZE for exocrine pancreatic insufficiency due to cystic fibrosis or other conditions; and STENDRA/SPEDRA for the treatment of erectile dysfunction. VIVUS intends to expand its product portfolio through expansion of the QSYMIA label into additional indications and the development of VI-0106, a Phase 2a/b candidate for the treatment of pulmonary hypertension. These near-term label expansion and pipeline opportunities, combined with the company’s commercial portfolio and experienced management team position VIVUS to create value for patients, healthcare payers and investors.